2019
Bone Quality and Fracture-Healing in Type-1 and Type-2 Diabetes Mellitus.
Henderson S, Ibe I, Cahill S, Chung YH, Lee FY. Bone Quality and Fracture-Healing in Type-1 and Type-2 Diabetes Mellitus. Journal Of Bone And Joint Surgery 2019, 101: 1399-1410. PMID: 31393433, DOI: 10.2106/jbjs.18.01297.Peer-Reviewed Original ResearchConceptsType 2 diabetesPerioperative complicationsDiabetic patientsGlycemic controlBone healthType 1Type 2 diabetes mellitusNormal bone mineral densityPerioperative glycemic controlNon-diabetic patientsEarly bone lossSurgical site infectionAppropriate glycemic controlUnion of fractureRisk of fractureBone mineral densityType 1 diabetesAntiresorptive therapyOperative interventionDiabetes mellitusSclerostin antibodySite infectionMedical managementParathyroid hormonePostoperative management
2014
A Review of Osteocyte Function and the Emerging Importance of Sclerostin
Compton JT, Lee FY. A Review of Osteocyte Function and the Emerging Importance of Sclerostin. Journal Of Bone And Joint Surgery 2014, 96: 1659-1668. PMID: 25274791, PMCID: PMC4179450, DOI: 10.2106/jbjs.m.01096.Peer-Reviewed Original ResearchConceptsBone massPhase III clinical trialsMetastatic bone diseaseOsteoporosis-related fracturesBone mineral densityBone cellsExtensive dendritic networkNormal physiologic stateSclerostin actsParathyroid hormoneInflammatory moleculesBone metabolismClinical trialsMineral densityProstaglandin E2Bone diseaseSystemic circulationOrthopedic conditionsProtein sclerostinOsseous integrationSclerostinBone cell populationsPhysiologic stateCell populationsOsteocyte function
2009
Zoledronate reduces unwanted bone resorption in intercalary bone allografts
Seo SW, Cho SK, Storer SK, Lee FY. Zoledronate reduces unwanted bone resorption in intercalary bone allografts. International Orthopaedics 2009, 34: 599-603. PMID: 19343345, PMCID: PMC2903128, DOI: 10.1007/s00264-009-0748-7.Peer-Reviewed Original ResearchConceptsAllograft resorptionIntercalary allograftsBone resorptionBone allograftControl groupZoledronate solutionIntercalary bone allograftsBone formationBone mineral densitySynthetic pyrophosphate analoguesHigh-dose bisphosphonatesPharmacological modificationGraft incorporationMineral densityBone densityAllograftsIdeal doseResorptionAnimal trialsHistological analysisBisphosphonatesSegmental defectsPyrophosphate analogsExperimental groupRat femur